

Lynette M Sholl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6956730/publications.pdf>

Version: 2024-02-01

232
papers

17,641
citations

16451

64
h-index

15732

125
g-index

234
all docs

234
docs citations

234
times ranked

21497
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	9.4	1,108
2	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	27.6	646
3	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 321-346.	2.5	586
4	<i>MET</i> Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , 2016, 34, 721-730.	1.6	549
5	Association of Polymerase β -Mutated and Microsatellite-Unstable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. <i>JAMA Oncology</i> , 2015, 1, 1319.	7.1	523
6	Assessment of Resistance Mechanisms and Clinical Implications in Patients With <i>EGFR</i> -Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018, 4, 1527.	7.1	522
7	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	1.1	515
8	Acquired Resistance to <i>KRAS</i> ^{G12C} Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2382-2393.	27.0	482
9	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	21.4	438
10	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358.	1.1	408
11	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	7.0	393
12	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. <i>Journal of Thoracic Oncology</i> , 2015, 10, 768-777.	1.1	357
13	Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 751-758.	2.5	350
14	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016, 1, e87062.	5.0	340
15	Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 5773-5779.	7.0	323
16	Suppression of STING Associated with LKB1 Loss in <i>KRAS</i> -Driven Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 34-45.	9.4	310
17	Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4532-4540.	7.0	307
18	The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy. <i>Cell</i> , 2014, 158, 564-578.	28.9	298

#	ARTICLE	IF	CITATIONS
19	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	5.5	278
20	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
21	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. <i>Modern Pathology</i> , 2020, 33, 2104-2114.	5.5	257
22	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 129-159.	2.8	241
23	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	1.1	234
24	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	1.1	203
25	Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. <i>Nature Communications</i> , 2020, 11, 6319.	12.8	203
26	Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. <i>Modern Pathology</i> , 2015, 28, 80-94.	5.5	190
27	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	1.1	182
28	ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1441-1449.	3.7	168
29	Breakmer: detection of structural variation in targeted massively parallel sequencing data using kmers. <i>Nucleic Acids Research</i> , 2015, 43, e19-e19.	14.5	161
30	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018, 24, 1038-1047.	7.0	154
31	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , 2016, 8, 79.	8.2	151
32	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
33	Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2013, 8, 322-328.	1.1	145
34	Sox2 Protein Expression is an Independent Poor Prognostic Indicator in Stage I Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1193-1198.	3.7	140
35	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016, 98, 1051-1066.	6.2	137
36	Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1334-1341.	9.4	133

#	ARTICLE	IF	CITATIONS
37	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
38	Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers. <i>Cancer Research</i> , 2009, 69, 8341-8348.	0.9	114
39	Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. <i>Modern Pathology</i> , 2015, 28, 1504-1514.	5.5	111
40	EGFR Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2010, 133, 922-934.	0.7	110
41	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. <i>JCI Insight</i> , 2016, 1, e89014.	5.0	110
42	Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. <i>Genetics in Medicine</i> , 2016, 18, 1011-1019.	2.4	108
43	Association of clonal hematopoiesis with chronic obstructive pulmonary disease. <i>Blood</i> , 2022, 139, 357-368.	1.4	106
44	Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. <i>Journal of Thoracic Oncology</i> , 2015, 10, 951-959.	1.1	100
45	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 56-62.	27.6	99
46	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2851-2860.	7.0	96
47	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1267-1272.	2.5	95
48	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	7.0	95
49	Sox2 Expression in Pulmonary Non-small Cell and Neuroendocrine Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 55-61.	1.2	91
50	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 34-42.	7.0	87
51	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021, 11, 1952-1969.	9.4	87
52	Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. <i>Modern Pathology</i> , 2015, 28, 732-739.	5.5	85
53	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	2.0	85
54	Targeted genomic analysis of Müllerian adenosarcoma. <i>Journal of Pathology</i> , 2015, 235, 37-49.	4.5	84

#	ARTICLE	IF	CITATIONS
55	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. <i>Oncolmunology</i> , 2017, 6, e1277308.	4.6	84
56	Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. <i>Lung Cancer</i> , 2014, 86, 241-246.	2.0	82
57	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. <i>Nature Communications</i> , 2017, 8, 14922.	12.8	80
58	Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 955-958.	5.6	78
59	Immunohistochemical Analysis of Langerin in Langerhans Cell Histiocytosis and Pulmonary Inflammatory and Infectious Diseases. <i>American Journal of Surgical Pathology</i> , 2007, 31, 947-952.	3.7	77
60	Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10299-10304.	7.1	77
61	Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 204-213.	7.0	73
62	Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF- κ B regulatory genes. <i>Modern Pathology</i> , 2016, 29, 67-74.	5.5	71
63	Clinical and Molecular Characteristics of <i>NF1</i> -Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3148-3156.	7.0	71
64	Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 660-672.	2.8	70
65	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. <i>Cancer Cytopathology</i> , 2018, 126, 253-263.	2.4	70
66	Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. <i>Modern Pathology</i> , 2019, 32, 830-843.	5.5	68
67	A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1464-1476.	5.6	67
68	Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. <i>Lung Cancer</i> , 2019, 134, 96-99.	2.0	67
69	Biomarkers in Lung Adenocarcinoma: A Decade of Progress. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 469-480.	2.5	66
70	KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2016, 11, 496-503.	1.1	65
71	Radiation-associated neoplasia: clinical, pathological and genomic correlates. <i>Histopathology</i> , 2017, 70, 70-80.	2.9	65
72	Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5963-5976.	7.0	63

#	ARTICLE	IF	CITATIONS
73	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016, 4, 1038-1048.	3.4	62
74	Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. <i>JAMA Oncology</i> , 2017, 3, 740.	7.1	61
75	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015, 3, 855-863.	3.4	60
76	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
77	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. <i>Cancer Immunology Research</i> , 2018, 6, 630-635.	3.4	59
78	Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2017, 125, 615-626.	2.4	58
79	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	58
80	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	3.3	56
81	Clinical Implications of Variant ALK FISH Rearrangement Patterns. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1648-1652.	1.1	52
82	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. <i>Laboratory Investigation</i> , 2020, 100, 4-15.	3.7	52
83	Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. <i>Modern Pathology</i> , 2007, 20, 1028-1035.	5.5	51
84	Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1434-1437.	1.1	51
85	Next-generation sequencing of cytologic preparations: An analysis of quality metrics. <i>Cancer Cytopathology</i> , 2017, 125, 786-794.	2.4	51
86	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
87	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 779-792.	1.1	50
88	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59.	4.1	49
89	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. <i>Modern Pathology</i> , 2018, 31, 1882-1890.	5.5	49
90	Characteristics of mismatch repair deficiency in sarcomas. <i>Modern Pathology</i> , 2019, 32, 977-987.	5.5	49

#	ARTICLE	IF	CITATIONS
91	SMARCA4 and Other SWItch/Sucose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	1.1	49
92	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. <i>Genetics in Medicine</i> , 2017, 19, 787-795.	2.4	46
93	Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. <i>Lung Cancer</i> , 2018, 122, 72-75.	2.0	46
94	Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. <i>Modern Pathology</i> , 2020, 33, 560-565.	5.5	46
95	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	7.3	45
96	Molecular diagnostics of lung cancer in the clinic. <i>Translational Lung Cancer Research</i> , 2017, 6, 560-569.	2.8	43
97	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3431-3442.	7.0	41
98	Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 626-635.	2.5	39
99	Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. <i>Leukemia and Lymphoma</i> , 2017, 58, 233-236.	1.3	39
100	Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019, 127, 285-296.	2.4	39
101	Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour. <i>Histopathology</i> , 2017, 70, 1138-1146.	2.9	38
102	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. <i>American Journal of Clinical Pathology</i> , 2019, 152, 97-108.	0.7	36
103	Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas. <i>Histopathology</i> , 2019, 75, 546-551.	2.9	35
104	Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. <i>Modern Pathology</i> , 2016, 29, 893-903.	5.5	33
105	GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 1720-1727.	5.5	33
106	Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. <i>Modern Pathology</i> , 2022, 35, 66-74.	5.5	33
107	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC. <i>Cancer Research</i> , 2014, 74, 4676-4684.	0.9	31
108	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015, 75, 3139-3146.	0.9	30

#	ARTICLE	IF	CITATIONS
109	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 814-821.	3.7	30
110	An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e131-e133.	1.1	30
111	Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1541-1548.	3.7	26
112	Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (MET 14) non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 8511-8511.	1.6	26
113	ARID1A mutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis. <i>Modern Pathology</i> , 2020, 33, 2256-2268.	5.5	25
114	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	7.0	25
115	The Molecular Pathology of Lung Cancer. <i>Surgical Pathology Clinics</i> , 2016, 9, 353-378.	1.7	23
116	Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1767-1772.	2.0	23
117	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020, 140, 35-41.	2.0	22
118	Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. <i>Genome Medicine</i> , 2022, 14, 39.	8.2	22
119	Successful Management of a Patient with Malignant Thyroid Teratoma. <i>Thyroid</i> , 2017, 27, 125-128.	4.5	21
120	Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 659-666.	2.9	20
121	Biallelic PTCH1 Inactivation Is a Dominant Genomic Change in Sporadic Keratocystic Odontogenic Tumors. <i>American Journal of Surgical Pathology</i> , 2020, 44, 553-560.	3.7	20
122	Malignant tumours of the uterus and ovaries with Mullerian and germ cell or trophoblastic components have a somatic origin and are characterised by genomic instability. <i>Histopathology</i> , 2020, 77, 788-797.	2.9	20
123	Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma. <i>Histopathology</i> , 2021, 78, 1032-1042.	2.9	20
124	Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. <i>Journal of Clinical Oncology</i> , 2016, 34, 11510-11510.	1.6	20
125	Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. <i>Human Pathology</i> , 2019, 86, 93-101.	2.0	19
126	Targeted Cancer Next-Generation Sequencing as a Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper Gastrointestinal Tract Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1246-1251.	2.5	18

#	ARTICLE	IF	CITATIONS
127	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). <i>Clinical Cancer Research</i> , 2021, 27, 1604-1611.	7.0	18
128	Myc protein expression correlates with MYC amplification in small cell lung carcinoma. <i>Histopathology</i> , 2015, 67, 81-89.	2.9	17
129	Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. <i>Journal of Oncology Practice</i> , 2017, 13, e185-e196.	2.5	17
130	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. <i>Annals of the American Thoracic Society</i> , 2020, 17, 550-554.	3.2	17
131	Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 92265-92274.	1.8	17
132	Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. <i>Modern Pathology</i> , 2022, 35, 1383-1397.	5.5	17
133	Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. <i>Cancer Genetics</i> , 2014, 207, 335-339.	0.4	16
134	Pseudoendocrine Sarcoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 33-43.	3.7	16
135	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. <i>Personalized Medicine</i> , 2017, 14, 37-50.	1.5	15
136	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. <i>Advances in Anatomic Pathology</i> , 2018, 25, 374-386.	4.3	15
137	Biobanking and cryopreservation of human lung explants for omic analysis. <i>European Respiratory Journal</i> , 2020, 55, 1801635.	6.7	15
138	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021, 15, 27-42.	4.6	15
139	Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. <i>Modern Pathology</i> , 2021, 34, 1935-1946.	5.5	15
140	Thymic Measurements in Pathologically Proven Normal Thymus and Thymic Hyperplasia. <i>Academic Radiology</i> , 2014, 21, 733-742.	2.5	14
141	Interactive or static reports to guide clinical interpretation of cancer genomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 458-464.	4.4	14
142	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1477-1489.	2.5	14
143	Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study. <i>Journal of Clinical Oncology</i> , 2019, 37, 9057-9057.	1.6	14
144	Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 401.	3.7	13

#	ARTICLE	IF	CITATIONS
145	Identification of a RAS-activating <i>TMEM87A</i> - <i>RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4072-4079.	7.0	13
146	<i>IER5</i> , a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation. <i>ELife</i> , 2020, 9, .	6.0	13
147	Mast cells in lung damage of COVID-19 autopsies: A descriptive study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2237-2239.	5.7	13
148	Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. <i>JCO Precision Oncology</i> , 2020, 4, 1084-1097.	3.0	11
149	Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. <i>Modern Pathology</i> , 2021, 34, 613-626.	5.5	11
150	A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1433-1451.	5.6	11
151	Quantitative computed tomography assessment of bronchiolitis obliterans syndrome after lung transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12943.	1.6	10
152	Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. <i>JCO Precision Oncology</i> , 2020, 4, 307-318.	3.0	10
153	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. <i>JCO Precision Oncology</i> , 2021, 5, 726-732.	3.0	10
154	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i> -mutant lung cancer. <i>Science Translational Medicine</i> , 2021, 13, eabb3738.	12.4	10
155	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	1.1	10
156	Emerging Evidence for MicroRNAs as Regulators of Cancer Stem Cells. <i>Cancers</i> , 2011, 3, 3957-3971.	3.7	9
157	Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 325-333.	1.5	9
158	Meningioma transcription factors link cell lineage with systemic metabolic cues. <i>Neuro-Oncology</i> , 2018, 20, 1331-1343.	1.2	9
159	Intestinal metaplasia of the urinary tract harbors potentially oncogenic genetic variants. <i>Modern Pathology</i> , 2021, 34, 457-468.	5.5	9
160	Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts. <i>Modern Pathology</i> , 2022, 35, 697-704.	5.5	9
161	Micropapillary adenocarcinoma of lung: Morphological criteria and diagnostic reproducibility among pulmonary pathologists. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 43-50.	1.3	8
162	Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes. <i>Modern Pathology</i> , 2021, 34, 1763-1779.	5.5	8

#	ARTICLE	IF	CITATIONS
163	Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer. , 2021, , .		8
164	Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. <i>Cancer Research</i> , 2020, 80, 3197-3199.	0.9	7
165	Predictive "biomarker piggybacking"™: an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry. <i>Histopathology</i> , 2021, 79, 260-264.	2.9	7
166	Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9069-9069.	1.6	7
167	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15113-e15113.	1.6	7
168	LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8596-TPS8596.	1.6	7
169	Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1464-1466.	1.1	6
170	Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9014-9014.	1.6	6
171	Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms. <i>Current Protocols in Human Genetics</i> , 2017, 92, 10.4.1-10.4.49.	3.5	5
172	Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 669-677.	1.2	5
173	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021, 10, 2627-2635.	2.8	5
174	Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8032-8032.	1.6	5
175	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100448.	3.0	5
176	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9018-9018.	1.6	4
177	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9082-9082.	1.6	4
178	Atypical uterine polyps show morphologic and molecular overlap with mullerian adenosarcoma but follow a benign clinical course. <i>Modern Pathology</i> , 2022, 35, 106-116.	5.5	4
179	Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR. <i>PLoS ONE</i> , 2022, 17, e0264201.	2.5	4
180	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9065-9065.	1.6	4

#	ARTICLE	IF	CITATIONS
181	Programmed death ligand 1 immunohistochemistry: can we agree on this?. <i>Histopathology</i> , 2020, 76, 189-190.	2.9	3
182	Superior Vena Cava Syndrome associated with recurrent uterine adenosarcoma. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100613.	0.6	3
183	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399.	2.1	3
184	Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. <i>Lung Cancer</i> , 2021, 157, 17-20.	2.0	3
185	Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5511-5511.	1.6	3
186	312 Three-year outcomes with first-line pembrolizumab for metastatic non-small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%. , 2021, 9, A336-A336.		3
187	Inflammatory myofibroblastic tumour-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma. <i>Histopathology</i> , 2016, 69, 510-515.	2.9	2
188	Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1433-1435.	1.1	2
189	Expanding the utility of cytology preparations in cancer biomarker testing. <i>Cancer Cytopathology</i> , 2021, 129, 337-340.	2.4	2
190	BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100127.	1.1	2
191	DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9113-9113.	1.6	2
192	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9121-9121.	1.6	2
193	Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): Implications for the NCI LungMAP study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8096-8096.	1.6	2
194	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9077-9077.	1.6	2
195	Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9577-9577.	1.6	2
196	Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1500-1500.	1.6	2
197	Neurotrophin Receptor Kinase. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 107-108.	2.8	2
198	Molecular Analysis of Genetic Markers for Non-Hodgkin Lymphomas. <i>Current Protocols in Human Genetics</i> , 2010, 65, Unit 10.14.1-25.	3.5	1

#	ARTICLE	IF	CITATIONS
199	Molecular Analysis of Genetic Markers for Non-Hodgkin Lymphomas. <i>Current Protocols in Human Genetics</i> , 2017, 93, 10.14.1-10.14.29.	3.5	1
200	Clinicopathological and molecular characteristics of prostate cancer diagnosed in young men aged up to 45 years. <i>Histopathology</i> , 2021, 78, 857-870.	2.9	1
201	Cancer patients' preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1535-1535.	1.6	1
202	Deliberations of a precision medicine tumor board. <i>Journal of Clinical Oncology</i> , 2016, 34, e13005-e13005.	1.6	1
203	Changes in tumor mutational burden in serially biopsied non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, e14286-e14286.	1.6	1
204	Pulmonary Clinicopathological Correlation In Long Term Survivors Following Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. <i>Blood</i> , 2013, 122, 2070-2070.	1.4	1
205	Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration. <i>Journal of Clinical Oncology</i> , 2014, 32, 8090-8090.	1.6	1
206	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3036-3036.	1.6	1
207	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 9066-9066.	1.6	1
208	Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloproliferative Neoplasms. <i>Current Protocols in Human Genetics</i> , 2010, 67, Unit 10.4.	3.5	0
209	Diagnosis of Primary and Metastatic Germ Cell Tumors Using Embryonic Stem Cell Transcription Factors. <i>Journal of Clinical Oncology</i> , 2013, 31, 177-186.		0
210	Commentary. <i>Clinical Chemistry</i> , 2015, 61, 587-588.	3.2	0
211	Preface. <i>Surgical Pathology Clinics</i> , 2016, 9, ix-x.	1.7	0
212	Poly (ADP Ribose) Polymerase Inhibitors for Cancer. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1126-1128.	2.8	0
213	Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100146.	1.1	0
214	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC. <i>Journal of Clinical Oncology</i> , 2021, 39, 9119-9119.	1.6	0
215	Changes in PD-L1 tumor proportion score are associated with CD274 gene (encoding PD-L1) copy number variation in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 9029-9029.	1.6	0
216	Diffuse Tracheobronchial Neurofibromatosis and Papillomatosis. Key Diagnostic Aspects and Treatment. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1000-1000.	1.3	0

#	ARTICLE	IF	CITATIONS
217	Ectopic Anterior Mediastinal Pancreas: An Unusual Case of New Onset Hemoptysis. <i>Annals of Thoracic Surgery</i> , 2021, , .	1.3	0
218	Abstract 26: Association of aneuploidy score with clinical outcomes to immunotherapy in NSCLC. , 2021, , .		0
219	In Response to "Reexamining the molecular findings in specialized stromal tumors of the prostate" <i>Modern Pathology</i> , 2021, 34, 2082-2083.	5.5	0
220	JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations.. <i>Blood</i> , 2007, 110, 1634-1634.	1.4	0
221	An analysis of the prevalence of <i>HER2</i> and <i>KRAS</i> mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8039-8039.	1.6	0
222	ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22042-e22042.	1.6	0
223	Medical management of pulmonary carcinoid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18512-e18512.	1.6	0
224	Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11030-11030.	1.6	0
225	Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11565-11565.	1.6	0
226	Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9577-9577.	1.6	0
227	General medical oncologists assessment and use of targeted treatment for patients (pts) with metastatic nonsquamous non-small cell lung cancer (nsqNSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e18186-e18186.	1.6	0
228	Optimizing somatic genomic reporting and physician interpretation with web-based, interactive technologies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1517-1517.	1.6	0
229	Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1513-1513.	1.6	0
230	Translocations as Predictive Biomarkers in Lung Cancer. <i>Molecular Pathology Library</i> , 2018, , 159-171.	0.1	0
231	Development of HOPE-Genomics: An IT platform for patient-directed cancer genome sequencing education and return of results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1532-1532.	1.6	0
232	Molecular assessment of paratesticular rhabdomyomas demonstrates recurrent findings, including a novel H3C2 p.K371 mutation. <i>Modern Pathology</i> , 0, , .	5.5	0